CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Genzyme Corporation v. Impax Laboratories, Inc.

1:09-cv-00653

Overview

Case Number 1:09-cv-00653
Filing Date 2009-03-13
Status Terminated
Termination Date 2012-09-10
Court District Court, D. Maryland (mdd)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand Defendant

Parties

Defendant

Endo Pharmaceuticals Inc. Operating Company

Represented By

2 Attorneys Listed

J Stephen Simms

Simms Showers LLP

Tel: +1 (410) 783-5795
Fax: +1 (410) 510-1789

201 International Circle, Suite 250

M Scotland Morris

Office of Inspector General

Tel: +1 (703) 248-4594

U.S. Postal Service, 1735 North Lynn Street

Impax Laboratories, Inc. Operating Company

Represented By

6 Attorneys Listed

Plaintiff

Genzyme Corporation NPE (Individual / Inventor)

Represented By

14 Attorneys Listed

Court & Judges

Court

District Court, D. Maryland (mdd)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 14 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts Counterparts in force
🏛️
USPTO PTAB Trials Counterparts in force
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (14): 🇺🇸 US
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6733780
Direct compression polymer tablet core
Filed: 2000-10-18
Issued: 2004-05-11
Expired (Term Ended)
Expires: 2020-10-18

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

59

Dispositive

7

Granted

16

Denied

0

Pending / Review

22

Motions by Category

Procedural / Extension Motion 25 Motion to Dismiss 7 Claim Construction / Markman Filing 11 Motion to Compel Discovery 10 Motion to Strike / Sanctions 6

Key Dispositive Motions & Rulings

Motion to Dismiss Pending / Under Review
NOTICE by Endo Pharmaceuticals Inc. re 51 MOTION to Intervene In Support of Genzyme Corporation's Motion to Dismiss Impax Laboratories, Inc.s (Impax) Countercla...
Entry #56 • 2009-09-16 Document →
Motion to Dismiss Pending / Under Review
MOTION to Intervene In Support of Genzyme Corporation's Motion to Dismiss Impax Laboratories, Inc.s (Impax) Counterclaims III and IV for Declaratory Judgment of...
Entry #51 • 2009-09-02 Document →
Motion to Dismiss Granted
Consent MOTION for Extension of Time to File Response/Reply as to 45 MOTION to Dismiss Impax Laboratories Inc.'s Counterclaims and for Declaratory Judgment of N...
Entry #46 • 2009-08-28 Document →
Motion to Dismiss Pending
MOTION to Dismiss Impax Laboratories Inc.'s Counterclaims and for Declaratory Judgment of No Infringement and Invalidity of the '780 Patent for Lack of Subject-...
Entry #45 • 2009-08-21 Document →
Motion to Dismiss Pending
MOTION to Dismiss Impax Laboratories Inc.'s Counterclaims and for Declaratory Judgment of No Infringement and Invalidity of the '780 Patent for Lack of Subject-...
Entry #45 • 2009-08-21 Document →
Motion to Dismiss Pending
MOTION to Dismiss Impax Laboratories Inc.'s Counterclaims and for Declaratory Judgment of No Infringement and Invalidity of the '780 Patent for Lack of Subject-...
Entry #45 • 2009-08-21 Document →

Docket Entries

(182 total)
Pleading / Complaint

COMPLAINT against Impax Laboratories, Inc. (Filing fee $ 350, receipt #14637032592), filed by Genzyme Corporation. (Attachments: # 1 Civil Cover Sheet, # 2 Exhibit A)(raf, Deputy Clerk) (Entered: 03/16/2009)

Entry #1 • 2009-03-13
1
Pleading / Complaint

COMPLAINT against Impax Laboratories, Inc. (Filing fee $ 350, receipt #14637032592), filed by Genzyme Corporation. (Attachments: # 1 Civil Cover Sheet, # 2 Exhibit A)(raf, Deputy Clerk) (Entered: 03/16/2009)

Entry #1 • 2009-03-13
2
Pleading / Complaint

COMPLAINT against Impax Laboratories, Inc. (Filing fee $ 350, receipt #14637032592), filed by Genzyme Corporation. (Attachments: # 1 Civil Cover Sheet, # 2 Exhibit A)(raf, Deputy Clerk) (Entered: 03/16/2009)

Entry #1 • 2009-03-13
2

Local Rule 103.3 Disclosure Statement by Genzyme Corporation. (raf, Deputy Clerk) (Entered: 03/16/2009)

Entry #2 • 2009-03-13
1

Summons Issued 20 days as to Impax Laboratories, Inc. (raf, Deputy Clerk) (Entered: 03/16/2009)

Entry #3 • 2009-03-16
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc